Platelet mitochondrial DNA and platelet RNA

Platelet mitochondrial DNA (mtDNA) and platelet RNA are the primary genetic and transcriptional components of anucleate platelets, playing pivotal roles in hemostasis, inflammation, and intercellular communication (NIH, 2014; ResearchGate, 2021). Despite lacking a nucleus, platelets contain functional mitochondria and a complex pool of RNAs—including messenger RNA (mRNA), microRNA (miRNA), and long non-coding RNA (lncRNA)—which are largely inherited from megakaryocytes (NIH, 2011; Clinical Epigenetics, 2015). These nucleic acids act as damage-associated molecular patterns (DAMPs) when released into the extracellular environment; specifically, platelet-derived mtDNA can activate Toll-like receptor 9 (TLR9), triggering pro-inflammatory and pro-thrombotic signaling pathways such as the NF-κB axis (Blood, 2025; Frontiers in Immunology, 2025). In disease states like cancer and cardiovascular disease, the platelet transcriptome and mtDNA methylation patterns undergo significant alterations, leading to the development of "tumor-educated platelets" (TEPs) whose RNA signatures serve as sensitive biomarkers for liquid biopsies (AACR, 2019; International Journal of Cardiology, 2024). Therapeutic strategies targeting these components include the use of anti-platelet agents like aspirin, which has been shown to inhibit platelet protein synthesis and alter RNA profiles, as well as TLR9 antagonists that block the inflammatory response to circulating mtDNA (NIH, 2021; NIH, 2025).

Other names

Platelet nucleic acidsPlatelet-derived mitochondrial DNAPlatelet transcriptomeTumor-educated platelet (TEP) RNAPlatelet-derived DAMPs

Inhibition of platelet activation to prevent the release of mitochondrial DNA and RNA; blockade of pattern recognition receptors (e.g., TLR9) that sense extracellular mitochondrial DNA; and modulation of intra-platelet protein synthesis and RNA stability.